Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Repaglinide (AG-EE 623ZW) is a benzoic acid derivative that stimulates insulin secretion from the pancreas and is used in the therapy of type 2 diabetes. Repaglinide has been linked to rare instances of clinically apparent acute liver injury.
パッケージサイズ | 在庫状況 | 単価(税別) | |||
---|---|---|---|---|---|
サンプルについてお問い合わせ | |||||
25 mg | 在庫あり | ¥ 10,000 | |||
50 mg | 在庫あり | ¥ 12,500 | |||
100 mg | 在庫あり | ¥ 18,500 | |||
200 mg | 在庫あり | ¥ 23,500 | |||
1 mL * 10 mM (in DMSO) | 在庫あり | ¥ 12,500 |
説明 | Repaglinide (AG-EE 623ZW) is a benzoic acid derivative that stimulates insulin secretion from the pancreas and is used in the therapy of type 2 diabetes. Repaglinide has been linked to rare instances of clinically apparent acute liver injury. |
別名 | AG-EE 388 ZW, AG-EE 623ZW |
分子量 | 452.59 |
分子式 | C27H36N2O4 |
CAS No. | 135062-02-1 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Ethanol: 84 mg/mL (185.6 mM)
DMSO: 55 mg/mL (121.52 mM)
H2O: < 1 mg/mL (insoluble or slightly soluble)
You can also refer to dose conversion for different animals. 詳細
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
Repaglinide 135062-02-1 DNA Damage/DNA Repair Membrane transporter/Ion channel Metabolism Potassium Channel PPAR mellitus. AG-EE 388 ZW AG-EE 623ZW inhibit Inhibitor benzoic type-2 insulin secretagogue CMBA diabetes acid carbamoylmethyl inhibitor